

# POLR3A variants in striatal involvement without diffuse hypomyelination

|       |   |
|-------|---|
| メタデータ | 言語: English<br>出版者:<br>公開日: 2021-05-01<br>キーワード (Ja):<br>キーワード (En):<br>作成者: Hiraide, Takuya, Kubota, Kazuo, Kono, Yu, Watanabe, Seiji, Matsubayashi, Tomoko, Nakashima, Mitsuko, Kaname, Tadashi, Fukao, Toshiyuki, Shimozawa, Nobuyuki, Ogata, Tsutomu, Saitsu, Hiroto<br>メールアドレス:<br>所属: |
| URL   | <a href="http://hdl.handle.net/10271/00003746">http://hdl.handle.net/10271/00003746</a>   |

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 International License.



1 **Case Report**

2 ***POLR3A* variants in striatal involvement without diffuse hypomyelination**

3 Takuya Hiraide<sup>1,2</sup>, Kazuo Kubota<sup>3,4</sup>, Yu Kono<sup>5</sup>, Seiji Watanabe<sup>6</sup>, Tomoko  
4 Matsubayashi<sup>6</sup>, Mitsuko Nakashima<sup>1</sup>, Tadashi Kaname<sup>7</sup>, Toshiyuki Fukao<sup>3,4</sup>, Nobuyuki  
5 Shimozawa<sup>4,8</sup>, Tsutomu Ogata<sup>2</sup> and Hiroto Saito<sup>1</sup>

6

7 <sup>1</sup>Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu,  
8 Japan; <sup>2</sup>Department of Pediatrics, Hamamatsu University School of Medicine,  
9 Hamamatsu, Japan; <sup>3</sup>Department of Pediatrics, Gifu University Graduate School of  
10 Medicine, Gifu, Japan; <sup>4</sup>Division of Clinical Genetics, Gifu University Hospital;  
11 <sup>5</sup>Department of Neurology, Fuji City General Hospital, Shizuoka, Japan; <sup>6</sup>Department  
12 of Pediatric Neurology, Shizuoka Children's Hospital, Shizuoka, Japan; <sup>7</sup>Department of  
13 Genome Medicine, National Center for Child Health and Development, Tokyo, Japan;  
14 <sup>8</sup>Division of Genomics Research, Life Science Research Center, Gifu University, Gifu,  
15 Japan.

16

17 Correspondence: Hiroto Saito, MD, PhD.

18 Department of Biochemistry, Hamamatsu University School of Medicine, 1-20-1  
19 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan

20 Tel/Fax: +81-53-435-2327

21 E-mail: hsaito@hama-med.ac.jp

22

23

1 **Abstract**

2 *Background:* Biallelic variants in *POLR3A* encoding the largest subunit of RNA  
3 polymerase III cause POLR3-related (or 4H) leukodystrophy characterized by  
4 neurologic dysfunction, abnormal dentition, endocrine abnormalities and ocular  
5 abnormality. Recently, whole-exome sequencing enabled the discovery of *POLR3A*  
6 variants in cases lacking diffuse hypomyelination, the principal MRI phenotype of  
7 POLR3-related leukodystrophy. Homozygous c.1771-6C>G variants in *POLR3A* were  
8 recently suggested to cause striatal and red nucleus involvement without white matter  
9 involvement.

10 *Case report:* Here, we report three cases in two families with biallelic *POLR3A*  
11 variants. We identified two sets of compound heterozygous variants in *POLR3A*,  
12 c.1771-6C>G and c.791C>T, p.(Pro264Leu) for family 1 and c.1771-6C>G and  
13 c.2671C>T, p.(Arg891\*) for family 2. Both families had the c.1771-6C>G variant,  
14 which led to aberrant mRNA splicing. Neuropsychiatric regression and severe  
15 intellectual disability were identified in three patients. Two cases showed dystonia and  
16 oligodontia. Notably, characteristic bilateral symmetric atrophy and abnormal signal of  
17 the striatum without diffuse white matter signal change were observed in brain MRI of  
18 all three individuals.

19 *Conclusions:* Striatum abnormalities may be another distinctive MRI finding associated  
20 with *POLR3A* variants, especially in cases including c.1771-6C>G variants and our  
21 cases can expand the phenotypic spectrum of *POLR3A*-related disorders.

22

- 1 **Keywords:** *POLR3A*, POLR3-related leukodystrophy, 4H leukodystrophy, striatal
- 2 involvement, whole-exome sequencing

## 1 **Introduction**

2 *POLR3A* (RNA polymerase III subunit A) encodes the catalytic component of RNA  
3 polymerase III (Pol III), which synthesizes small RNAs such as nuclear-encoded  
4 transfer RNAs (tRNA) and various other small housekeeping noncoding RNAs  
5 (ncRNA) [1]. Biallelic *POLR3A* variants cause POLR3-related (or 4H) leukodystrophy  
6 (OMIM # 607694), which is characterized by neurologic dysfunction, abnormal  
7 dentition, endocrine abnormalities and ocular abnormality [2]. POLR3-related  
8 leukodystrophy showed characteristic magnetic resonance imaging (MRI) findings  
9 including high-intensity areas in the white matter on the T2-weighted images, cerebellar  
10 atrophy and thinning of the corpus callosum [3].

11 Recent studies described several cases with *POLR3A* variants who did not show  
12 diffuse hypomyelination [4-7]. Azmanov et al. indicated that striatal and red nucleus  
13 involvement without white matter involvement was observed in individuals with a  
14 homozygous splice site variant (c.1771-6C>G) in *POLR3A* [5].

15 Here, we report three individuals with biallelic *POLR3A* variants including  
16 c.1771-6C>G, who show characteristic brain images of striatal lesions without  
17 abnormal signal changes of white matter. We reviewed the literature and discussed the  
18 phenotypic features of *POLR3A*-related disorders.

## 19 **Genetic analyses**

20 This study was approved by the Institutional Review Board Committee at Hamamatsu  
21 University School of Medicine. After receiving written informed consent, genomic  
22 DNAs extracted from peripheral blood samples from the probands and their parents  
23 were analyzed using whole-exome sequencing (WES). Data processing, variant calling,

1 annotation and filtering were performed as described previously [8]. Using the  
2 trio-WES data, we found compound heterozygous variants in *POLR3A* (NM\_007055.4),  
3 c.1771-6C>G and c.791C>T, p.(Pro264Leu) in patient 1 and c.1771-6C>G and  
4 c.2671C>T, p.(Arg891\*) in patient 2 (Figure 1A). These variants were validated using  
5 Sanger sequencing of the two patients and patient 3, an affected younger sister of  
6 patient 2 (Figure 1A). A previous study revealed that the c.1771-6C>G variant caused  
7 skipping of exon 14 in the mutant transcript, which introduced the premature  
8 termination codon (p.(Pro591Metfs\*9)) [5]. The novel c.791C>T and the c.2671C>T  
9 variants are absent in the public databases and predicted to be deleterious by *in silico*  
10 pathogenicity prediction tools (Supplemental Table S1). These findings suggested that  
11 these *POLR3A* variants were likely to be pathogenic in our cases.

12

## 13 **Case Presentation**

### 14 **Patient 1**

15 After 37 weeks of gestation without asphyxia, a Japanese boy was born to  
16 nonconsanguineous healthy parents as their first child (Figure 1A). There was no family  
17 history of neurodevelopmental disorders. He had thick lips and thick eyebrows (Figure  
18 2A), but no dental abnormalities were found (Figure 2B). His developmental milestones  
19 were delayed: head control at 6 months and walking independently at 1 year and 5  
20 months. He was diagnosed with autism spectrum disorder at 3 years. He began speaking  
21 meaningful words at 4 years, but could not combine two words. Dysarthria developed at  
22 8 years and progressed. His gait was unstable whenever he started walking, but he was  
23 able to go up and down the stairs at 6 years old. However, his motor dysfunction

1 gradually regressed and he could not walk unsupported because of progressive gait  
2 ataxia and muscle hypotonia at 11 years old. Brain MRI at 12 years old revealed  
3 bilateral symmetric atrophy and increased signal of the caudate nucleus and the putamen  
4 (Figure 2D, H). The white matter and red nucleus showed no abnormal signal changes,  
5 and cerebellum was normal (Figure 2E, I). Upon final examination at 18 years old, he  
6 could not maintain a sitting position without support. He showed tremor but no dystonia  
7 or rigidity. He was unable to speak any words, but he could communicate with others  
8 using a letter board.

9

## 10 **Patient 2**

11 A Japanese girl was born to nonconsanguineous healthy parents without asphyxia as a  
12 second child after an uneventful 40-week pregnancy. The first child was stillborn after 7  
13 months of gestation. Her developmental milestones were normal until 1 year: head  
14 control at 4 months and pulling herself up at 10 months. Thereafter, her development  
15 regressed: she could not pull herself to standing at 1 year and 6 months and she could  
16 not sit unassisted at 2 years old. She thrashed her extremities randomly since the age of  
17 1 year and 6 months; these were considered progressive hyperkinetic movements.  
18 Progressive muscle hypotonia, dysarthria, ophthalmoparesis and dystonia were noted.  
19 Biochemical analyses of blood and metabolic screenings including amino acids, lactic  
20 acid and pyruvic acid were unremarkable. MRI at 8 years showed bilateral symmetric  
21 atrophy and increased signal of the striatum and cerebral atrophy (Figure 2F, J). The red  
22 nucleus and cerebellum were normal. At 23 years old, she was bedridden and received

1 tube feeding from the gastrostoma. Severe dystonia, rigidity and congenital hypodontia  
2 was observed (Figure 2C).

### 3 4 **Patient 3**

5 A Japanese girl was born without asphyxia as a third child after 38 weeks of gestation.  
6 Her older sister was patient 2. Her development was normal until 1 year of age. She  
7 could hold her head up at 3 months and could pull herself up at 11 months. However,  
8 she stopped laughing at 1 year and she could not stand up even with support at 1 year  
9 and 9 months. Myoclonus was recognized at 1 year and 5 months, and dystonia was  
10 seen at 1 year and 11 months. Tube feeding started because of dysphagia at 3 years and  
11 gastrostomy was performed at 8 years. Home ventilator therapy was initiated at 9 years.  
12 The biochemical analyses of blood and metabolic screenings including amino acids,  
13 lactic acid and pyruvic acid showed normal values. Brain MRI at 10 years old showed  
14 bilateral-atrophy-associated increased signal in the striatum and frontal predominant  
15 cerebral atrophy (Figure 2G, K). Neither signal changes in red nucleus nor cerebellar  
16 atrophy were recognized. She died at 15 because of respiratory disturbance due to  
17 increased tracheal granulation.

### 18 19 **Discussion**

20 In this study, we described three individuals with compound heterozygous *POLR3A*  
21 variants. We summarized the clinical manifestations of eight patients who shared  
22 c.1771-6C>G variant including our cases in Table 1 [4-6]. Dystonia (6/8), ataxia (6/8),  
23 dysphagia (5/8), muscle weakness (4/8) and Babinski sign (4/8) were frequently



1 observed. Cerebellar features like ataxia, dysphagia and mild pyramidal features  
2 overlapped with those of POLR3-related leukodystrophy [2]. Other common features of  
3 POLR3-related leukodystrophy, including dental abnormalities (3/8), hypogonadism  
4 (0/6) and developmental delay (2/7) [3], were found in a minority of patients.  
5 Extrapyrarnidal signs are not commonly seen in patients with POLR3-related  
6 leukodystrophy [3]; however, most individuals had dystonia. Considering these  
7 findings, extrapyramidal signs may be characteristic physical features for patients with  
8 c.1771-6C>G variants.

9 *POLR3A* variants have been identified in individuals with neurological disorders such  
10 as hereditary ataxia and spastic paraparesis (Figure 1B) [6,7]. Brain images of these  
11 cases showed various brain abnormalities; abnormal signal of the posterior limb of the  
12 internal capsule, involvement of superior cerebellar peduncles, thin cervical spinal cord,  
13 cerebellar atrophy and thin corpus callosum [6,7]. Furthermore, atypical brain  
14 abnormalities without diffuse hypomyelination, including a selective involvement of the  
15 corticospinal tracts or moderate to severe cerebellar atrophy, were reported in cases of  
16 POLR3-related leukodystrophy [4]. MRI findings of eight cases with c.1771-6C>G  
17 variant also showed no signal changes of white matter, but the caudate nucleus and  
18 putamen involvement were observed in six of the eight individuals. Interestingly,  
19 striatal involvement was recognized only in individuals with c.1771-6C>G variants.  
20 Therefore, our study expands MRI phenotypes of brain abnormalities associated with  
21 *POLR3A* variants.

22 Although the underlying mechanism of *POLR3A*-related disorders is unsolved,  
23 dysregulation of tRNAs expression and RNA polymerase III transcribed ncRNAs may

1 impair the myelin development and maintenance [9]. Homozygous c.1771-6C>G  
2 variants in *POLR3A* reduced Pol III-transcribed tRNA expression and affected the  
3 balance of tRNAs and ncRNAs [5]. Recent studies suggested that tRNA  
4 hypomodification and tRNA-modifying-enzyme deregulation affected the efficiency  
5 and fidelity of protein translation and were associated with developments of several  
6 neurodegenerative diseases [10]. Thus, in patients with c.1771-6C>G variant, it is  
7 possible that disturbance of Pol III transcription involving tRNAs could affect proper  
8 translation and impair cellular processes, especially in the striatum.

9 In conclusion, we identified three cases with neuropsychiatric regression with  
10 characteristic striatal involvements without diffuse hypomyelination related to the  
11 c.1771-6C>G splicing variant in *POLR3A*. Our cases expand the phenotypic spectrum  
12 of POLR3-related leukodystrophy.

13

#### 14 **Acknowledgments**

15 We would like to thank the patients' families for participating in this work. This work  
16 was supported by the Japan Agency for Medical Research and Development (AMED)  
17 (JP19ek0109301 to T.O. and JP19ek0109297 to H.S.).

#### 18 **Conflict of Interest**

19 The authors declare that they have no conflicts of interest.

20

## 1   **References**

- 2   1. Dieci G, Fiorino G, Castelnuovo M, Teichmann M, Pagano A. The expanding RNA  
3       polymerase III transcriptome. *Trends Genet.* 2007;23:614-22.
- 4   2. Bernard G, Vanderver A. POLR3-Related Leukodystrophy. In: Adam MP,  
5       Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors.  
6       GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle;  
7       1993-2019. 2012 Aug 2 [updated 2017 May 11]. Available from:  
8       <https://www.ncbi.nlm.nih.gov/books/NBK99167/>
- 9   3. Wolf NI, Vanderver A, van Spaendonk RM, Schiffmann R, Brais B, Bugiani M, et  
10       al. Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B  
11       mutations. *Neurology.* 2014;83:1898-905.
- 12   4. La Piana R, Cayami FK, Tran LT, Guerrero K, van Spaendonk R, Öunap K, et al.  
13       Diffuse hypomyelination is not obligate for POLR3-related disorders. *Neurology.*  
14       2016;86:1622-6.
- 15   5. Azmanov DN, Siira SJ, Chamova T, Kaprelyan A, Guergueltcheva V, Shearwood  
16       AJ1, et al. Transcriptome-wide effects of a POLR3A gene mutation in patients with  
17       an unusual phenotype of striatal involvement. *Hum Mol Genet.* 2016;25:4302-14.
- 18   6. Rydning SL, Koht J, Sheng Y, Sowa P, Hjorthaug HS, Wedding IM, et al. Biallelic  
19       POLR3A variants confirmed as a frequent cause of hereditary ataxia and spastic  
20       paraparesis. *Brain.* 2019;142:e12.
- 21   7. Minnerop M, Kurzwelly D, Wagner H, Soehn AS, Reichbauer J, Tao F, et al.  
22       Hypomorphic mutations in POLR3A are a frequent cause of sporadic and recessive  
23       spastic ataxia. *Brain.* 2017;140:1561-78.

- 1 8. Miyamoto S, Nakashima M, Ohashi T, Hiraide T, Kurosawa K, Yamamoto T, et al.  
2 A case of de novo splice site variant in SLC35A2 showing developmental delays,  
3 spastic paraplegia, and delayed myelination. *Mol Genet Genomic Med.*  
4 2019;7:e814.
- 5 9. Choquet K, Forget D, Meloche E, Dicaire MJ, Bernard G, Vanderver A, et al.  
6 Leukodystrophy-associated POLR3A mutations down-regulate the RNA  
7 polymerase III transcript and important regulatory RNA BC200. *J Biol Chem.*  
8 2019;294:7445-59.
- 9 10. Pereira M, Francisco S, Varanda AS, Santos M, Santos MAS, Soares AR. Impact of  
10 tRNA Modifications and tRNA-Modifying Enzymes on Proteostasis and Human  
11 Disease. *Int J Mol Sci.* 2018;19:3738.
- 12  
13  
14  
15

1 **Figure legends**

2 **Figure 1.** Pedigrees and schematic structure of *POLR3A*

3 (A) Familial pedigrees and Sanger sequencing confirmation of Family 1 and Family 2.  
4 *POLR3A* (NM\_007055.4) variants are shown below each individual. Arrows, probands;  
5 SB, stillbirth; WT, wild-type allele of *POLR3A*. (B) Schematic presentation of RPC1  
6 protein encoded by *POLR3A* and location of altered residues. Previously-reported  
7 *POLR3A* variants, which showed no diffuse hypomyelination, are depicted above  
8 (previously reported in spastic ataxia [6,7], blue; previously reported in the cases with  
9 selective involvement of the corticospinal tracts or cerebellar atrophy [4], purple). The  
10 *POLR3A* variants identified in our case are shown below. Multiple amino acid  
11 sequences of RPC1 were aligned using the ClustalW tool (see  
12 <http://www.genome.jp/tools/clustalw>). The c.791C>T variant was highly evolutionarily  
13 conserved.

14

15 **Figure 2.** Clinical features of patients with *POLR3A* variants

16 (A, B) Photographs of patient 1 at 18 years old. Thick lips and thick eyebrows are  
17 observed (A), but no dental abnormalities are recognized (B). (C) A dental cavity  
18 photograph of patient 2 taken at 23 years old shows hypodontia. Eight upper and lower  
19 anterior teeth and molars were lacking. (D-K) MRI of three patients: patient 1 at 12  
20 years old (D, E, H, I), patient 2 at 8 years old (F, J), patient 3 at 10 years old (G, K).  
21 Axial (D-G) and a coronal (H) T2-weighted image and a coronal T2–fluid-attenuated  
22 inversion recovery image (J) all show elevated signal of the caudate nucleus and the  
23 putamen and bilateral symmetric atrophy. Frontal predominant brain atrophies are

1 recognized in patients 2 and 3 (F, G). No signal change in red nucleus is seen in an axial  
2 T2-weighted image (E). A sagittal T1-weighted image shows no cerebellar atrophy (I).  
3 An axial T1-weighted image reveals hypointensity of putamen (K). We obtained written  
4 informed consents to post these photographs and images from their parents.

5

6

1 **Table 1.** Clinical findings of individuals with c.1771-6C>G variant in *POLR3A* variants [4-6].

| Individuals                            | This study                       |                                   |                                   | Azmanov et al.                    |                                   |                                   | Rydning et al.                    | La Piana et al.                   |
|--|----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|  | Patient 1                        | Patient 2                         | Patient 3                         | ShII-1                            | IzII-1                            | IzII-2                            |                                   |                                   |
| Variant 1                              | c.1771-6C>G<br>p.(Pro591Metfs*9) | c.1771-6C>G<br>p.(Pro591Metfs*10) | c.1771-6C>G<br>p.(Pro591Metfs*11) | c.1771-6C>G<br>p.(Pro591Metfs*12) | c.1771-6C>G<br>p.(Pro591Metfs*13) | c.1771-6C>G<br>p.(Pro591Metfs*14) | c.1771-6C>G<br>p.(Pro591Metfs*16) | c.1771-6C>G<br>p.(Pro591Metfs*15) |
| Variant 2                              | c.791C>T<br>p.(Pro264Leu)        | c.2671C>T<br>p.(Arg891*)          | c.2671C>T<br>p.(Arg891*)          |                                   |                                   |                                   |                                   | c.3205C>T<br>p.(Arg1069Trp)       |
| Status                                 | C Het                            | C Het                             | C Het                             | Homo                              | Homo                              | Homo                              | Homo                              | C Het                             |
| Sex, age                               | M, 18 years                      | F, 23years                        | F, 15 years (died)                | M, 52 years                       | M, 27 years                       | M, 23 years                       | M, 41 years                       | NA                                |
| Age at onset                           | 6 months                         | 1 year and 6 months               | 1 year                            | 8 years                           | 7 years                           | 8 years                           | 4 years                           | NA                                |
| <i>Upper motor neuron signs</i>        |                                  |                                   |                                   |                                   |                                   |                                   |                                   |                                   |
| Muscle weakness                        | +                                | +                                 | +                                 | -                                 | -                                 | -                                 | +                                 | NA                                |
| Spasticity                             | -                                | -                                 | NA                                | -                                 | -                                 | -                                 | +                                 | +                                 |
| Brisk tendon reflexes                  | -                                | +                                 | NA                                | +                                 | -                                 | -                                 | -                                 | NA                                |
| Babinski sign                          | -                                | -                                 | NA                                | +                                 | +                                 | +                                 | +                                 | NA                                |
| <i>Extrapyramidal signs</i>            |                                  |                                   |                                   |                                   |                                   |                                   |                                   |                                   |
| Rigidity                               | -                                | +                                 | NA                                | +                                 | +                                 | -                                 | NA                                | NA                                |
| Dystonia                               | -                                | +                                 | +                                 | +                                 | +                                 | +                                 | +                                 | NA                                |
| Tremor                                 | +                                | -                                 | NA                                | -                                 | -                                 | -                                 | +                                 | NA                                |
| <i>Cerebellar features</i>             |                                  |                                   |                                   |                                   |                                   |                                   |                                   |                                   |
| Ataxia                                 | +                                | -                                 | NA                                | +                                 | +                                 | +                                 | +                                 | +                                 |
| Gaze-evoked nystagmus                  | -                                | +                                 | +                                 | +                                 | -                                 | -                                 | -                                 | NA                                |
| Abnormal smooth pursuits               | -                                | +                                 | NA                                | +                                 | -                                 | -                                 | -                                 | NA                                |
| Dysphagia                              | +                                | +                                 | +                                 | -                                 | +                                 | -                                 | +                                 | NA                                |
| Developmental delay                    | +                                | -                                 | -                                 | -                                 | -                                 | -                                 | NA                                | +                                 |
| Intellectual disability                | +                                | +                                 | +                                 | -                                 | -                                 | -                                 | NA                                | NA                                |
| Neuropsychiatric regression            | +                                | +                                 | +                                 | -                                 | -                                 | -                                 | NA                                | NA                                |
| <i>Neuroimaging</i>                    |                                  |                                   |                                   |                                   |                                   |                                   |                                   |                                   |
| Signal changes in diffuse white matter | -                                | -                                 | -                                 | -                                 | -                                 | -                                 | -                                 | -                                 |
| Atrophy and signal changes in striatum | +                                | +                                 | +                                 | +                                 | +                                 | +                                 | NA                                | NA                                |
| Signal changes in red nucleus          | -                                | -                                 | -                                 | +                                 | +                                 | +                                 | NA                                | NA                                |
| PLIC                                   | -                                | -                                 | -                                 | -                                 | -                                 | -                                 | +                                 | +                                 |
| SCP hyperintensity                     | -                                | -                                 | -                                 | NA                                | NA                                | NA                                | +                                 | NA                                |
| Thin cervical spinal                   | -                                | -                                 | -                                 | NA                                | NA                                | NA                                | +                                 | NA                                |










|                      |   |   |    |   |   |                     |                     |         |    |
|----------------------|---|---|----|---|---|---------------------|---------------------|---------|----|
| cord                 |   |   |    |   |   |                     |                     |         |    |
| Cerebellar atrophy   | - | - | -  | - | - | -                   | -                   | +       | -  |
| Limb deformities     | - | - | -  | - | - | Bilateral pes cavus | Bilateral pes cavus | -       | NA |
| Dental abnormalities | - | + | +  | - | - | -                   | -                   | -       | +  |
| Hypogonadism         | - | - | NA | - | - | -                   | -                   | -       | NA |
| Others               |   |   |    |   |   |                     |                     | LD, HSP |    |

C Het, compound heterozygous; HSP, hereditary spastic paraparesis; LD, learning difficulties; NA not assessed or not available; PLIC, Abnormal signal of the posterior limb of the internal capsule; SCP, superior cerebellar peduncles

1  
2







**Table S1. Allele frequency and *in silico* prediction of *POLR3A* variants (NM\_007055.4)**

| Family | Variant                           | 3.5KJPN | gnomAD     | SIFT  | PP2<br>HVAR | CADD<br>phred | M-CAP | Mutation<br>Taster |
|--------|-----------------------------------|---------|------------|-------|-------------|---------------|-------|--------------------|
| I, II  | c.1771-6C>G,<br>p.(Pro591Metfs*9) | 0.0004  | 0.00006024 |       |             | 11.52         |       |                    |
| I      | c.791C>T,<br>p.(Pro264Leu)        | –       | –          | 0.001 | 0.977       | 28.6          | 0.751 | 1                  |
| II     | c.2671C>T,<br>p.(Arg891*)         | –       | –          |       |             | 39            |       |                    |

3.5KJPN, <https://jmorp.megabank.tohoku.ac.jp/>; gnomAD (the Genome Aggregation Database), <http://gnomad.broadinstitute.org/>; SIFT (Sorting Intolerant From Tolerant), <http://sift.jcvi.org/>; Polyphen-2 Hum Var, <http://genetics.bwh.harvard.edu/pph2/>; CADD (Combined Annotation–Dependent Depletion), <http://cadd.gs.washington.edu/score>; M-CAP (Mendelian Clinically Applicable Pathogenicity), <http://bejerano.stanford.edu/mcap/index.html>; MutationTaster, <http://www.mutationtaster.org/>.